The science

Ancient viruses, modern disease

GeNeuro was founded on a radical but evidence-backed hypothesis: that a class of ancient viral sequences permanently embedded in the human genome — human endogenous retroviruses — are a root cause of some of the most devastating neurological and autoimmune diseases of our time, including Multiple Sclerosis, ALS, Psychosis, Type 1 Diabetes, and Long Covid Brain Fog.

What are HERVs?

Over millions of years, retroviruses infected our ancestors and integrated their genetic material into the germline — passing their sequences to every subsequent generation. Today, these sequences, known as human endogenous retroviruses (HERVs), make up approximately 8% of the human genome.

Under normal circumstances, these sequences remain silenced. But environmental triggers — viral infections, inflammation, immune dysregulation — can reactivate them. When reactivated, HERV genes produce proteins that the immune system has never learned to tolerate, triggering a cascade of neuroinflammation and tissue damage.

8%
of the human genome is HERV-derived
~100,000
HERV elements in the human genome
50+
years of HERV research underpins our platform

How HERV reactivation drives disease

The pathogenic mechanism

01

Trigger event

An environmental trigger — viral infection (e.g. SARS-CoV-2, EBV, HSV), inflammation, or immune stress — activates dormant HERV sequences. This mechanism is now implicated in Long Covid, where SARS-CoV-2 infection drives persistent HERV-W reactivation and neuroinflammation.

02

HERV protein expression

Reactivated HERV genes produce envelope proteins (e.g. HERV-W Env, HERV-K) that are foreign to the immune system.

03

Neuroinflammation

HERV proteins activate Toll-like receptors and microglia, triggering a sustained neuroinflammatory response.

04

Tissue damage

Chronic inflammation leads to demyelination, neurodegeneration, and progressive loss of function — the hallmarks of MS, ALS, and related diseases.

Trigger EventVirus activates dormant HERVHERV Protein ExpressionEnv proteins releasedNeuroinflammationMicroglia & TLR activationTissue DamageDemyelination & neurodegeneration01020304

Our approach

The GeNeuro platform

GeNeuro has developed a portfolio of monoclonal antibodies that specifically neutralize pathogenic HERV proteins. By targeting the upstream driver of neuroinflammation — rather than its downstream effects — our approach aims to modify disease course rather than merely manage symptoms.

View clinical pipeline

Upstream targeting

Neutralizing HERV proteins at the source, before the inflammatory cascade begins.

Precision antibodies

Monoclonal antibodies engineered for high specificity against HERV envelope proteins.

Broad applicability

The same HERV-W pathway implicated in MS is also active in psychosis, Type 1 Diabetes, Long Covid Brain Fog, and other immune-mediated diseases.

Clinical & institutional validation

Phase I and Phase II data demonstrate safety, tolerability, and efficacy signals. The ALS program was developed under a CRADA with the NIH/NINDS, with GNK-301 shown to prevent motor neuron degeneration in preclinical models.

Selected publications

Annals of Neurology · 2022

Human Endogenous Retrovirus K Envelope in Spinal Fluid of Amyotrophic Lateral Sclerosis Is Toxic

Steiner JP, Bachani M, Malik N, … Perron H, Nath A

PubMed 35801347

iScience · 2023

SARS-CoV-2 awakens ancient retroviral genes and the expression of proinflammatory HERV-W envelope protein in COVID-19 patients

Charvet B, Brunel J, Pierquin J, … Perron H, Horvat B

PubMed 37091988

Proceedings of the National Academy of Sciences · 2023

Transgenic expression of the HERV-W envelope protein leads to polarized glial cell populations and a neurodegenerative environment

Gruchot J, Lewen I, Dietrich M, … Perron H, Küry P

PubMed 37695891

Translational Psychiatry · 2023

Patients with psychosis spectrum disorders hospitalized during the COVID-19 pandemic unravel overlooked SARS-CoV-2 past infection clustering with HERV-W ENV expression and chronic inflammation

Tamouza R, Meyer U, Lucas A, … Perron H, Leboyer M

PubMed 37524719

Frontiers in Immunology · 2022

HERV-W ENV antigenemia and correlation of increased anti-SARS-CoV-2 immunoglobulin levels with post-COVID-19 symptoms

Giménez-Orenga K, Pierquin J, Brunel J, Charvet B, … Perron H, Oltra E

PubMed 36389746

Molecular Psychiatry · 2025

Recapitulation and reversal of neuropsychiatric phenotypes in a mouse model of human endogenous retrovirus type W expression

Herrero F, Heeb C, Meier M, … Perron H, Küry P, Meyer U

PubMed 40102613

Microbes and Infection · 2025

HERV-W ENV transcription in B cells predicting symptomatic COVID-19 and risk for long COVID can express a full-length protein despite stop codon in mRNA from chromosome X via a ribosome readthrough

Brunel J, Paganini J, Galloux M, Charvet B, Perron H

PubMed 39419470